Cell lysis is the first step of protein extraction, which is further used for different application such as enzyme engineering and protein labelling. Furthermore, cell lysis is also an important step to study protein -protein interaction, which supports growth of cell lysis market. Players in the global cell lysis market are focusing on investing in R&D, to introduce advanced products used in cell lysis process. Furthermore, increasing demand for cell-based therapy for treatment purpose of cancer is also expected to augment growth of the cell lysis market. For instance, in 2017, US-based manufacturers Zymo Research Corp. and Bertin Technologies collaborated to develop real-time sample lysis step, which is carried out only in one minute.
The global cell lysis market was valued at US$ 2,715.1 billion in 2017 and is expected to witness a CAGR of 8.6 % over the forecast period (2017–2025).
Robust research and development is expected to Drive Growth of the Cell Lysis Market
Increasing research and development in the field of proteomics and genomics and high prevalence of infectious disease and cancer are the major factors driving growth of the cell lysis market. For instance, According to 2012 EU Industrial R&D Investment Scoreboard, the pharmaceutical and biotechnology sectors represented 17.7% of business R&D expenditure in the world. Furthermore, in 2017, the FDA approved 2 CAR-T cell therapy for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia and adult patients with certain types of large B-cell lymphoma. Such advancement in cell-based therapy support the growth of cell lysis market. However, high cost of cell based research, owing to high expenditure in research and development for CAR-T cell therapy may hamper the growth of the market as The FDA approved CAR T-Cell therapy is priced at US$ 475,000 for single infusion for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia. Moreover, this cost does not include pre-infusion treatment cost, drug administration, hospitalization costs, and costs associated with adverse events and follow-up care
Increase in Prevalence of Cancer Cases is also Driving Growth of the Cell Lysis Market
Rise in prevalence of infectious disease and cancer cases in various regions of the world leads to more utilization of cell samples for research and development of drugs thus, expected to have a meteoric growth for the cell lysis market. For instance, According to the estimates by GLOBOCAN 2012, an estimated 850,000 new cancer cases were diagnosed in Africa, while almost 600,000 deaths were attributed to malignant disease. The number of cancer cases is expected to rise to 1,056,000 by 2020. Furthermore, According to the World Health Organization (WHO), in 2012, around 3,319 deaths occurred due to the infectious and parasitic disease infection, in Sub Saharan Africa region and according to the same source, in 2014, Ebola accounted around 8,000 deaths in this region.
Increase in collaboration among government and market players is also expected to propel the cell lysis market growth during the forecast period. For instance, in September, 2015 African Academy of Sciences (AAS) and the New Partnership for Africa’s Development (NEPAD) Agency with got US$5.5 million in initial seed funding from the Bill & Melinda Gates Foundation, the Wellcome Trust and the UK Department for International Development launched Alliance for Accelerating Excellence in Africa (AESA). Furthermore, in 2016, Thermofisher scientific, Inc. partnered with Hamilton Bonaduz AG, to accelerate automation platform’s access to forensic customers. The automation platform includes AutoLys STAR 4×4 for sample lysis and DNA purification, which is the only hand-free automation solution for lysis and DNA extraction.
Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/741
Cell Lysis Market – Key Players
Major Key players involved in cell lysis market includes: Thermo Fisher Scientific Inc., Merck & Co. Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., and Qsonica.